Integrative analysis of hub genes for recurrent pregnancy loss with antiphospholipid syndrome: integrated bioinformatics analysis, machine learning and experimental validation - Summary - MDSpire
Advertisement
Integrative analysis of hub genes for recurrent pregnancy loss with antiphospholipid syndrome: integrated bioinformatics analysis, machine learning and experimental validation
To identify potential hub genes for APS-related RPL and provide insights into its pathogenesis and potential diagnostic strategies, emphasizing the clinical relevance.
Key Findings:
Identified 10 common DEGs, with eight downregulated and two upregulated genes, highlighting their potential roles in RPL.
Imbalance of immune system-associated cells and molecules is a common characteristic in APS and RPL, suggesting a shared pathophysiology.
NAA30, ARHGAP44, and SUGT1 were identified as hub genes, with implications for targeted therapies.
SUGT1 was downregulated in RPL with APS and influenced trophoblast cell behavior, indicating its potential as a therapeutic target.
Interpretation:
The study provides insights into the molecular mechanisms underlying RPL with APS and identifies potential biomarkers and therapeutic targets.
Limitations:
The study relies on data from public databases, which may have inherent biases affecting the generalizability of findings.
Experimental validation was limited to a few hub genes, necessitating further studies to confirm their roles.
Conclusion:
The findings offer novel insights into the biological mechanisms underlying RPL with APS and support the development of targeted therapeutic strategies, potentially influencing clinical practices.
Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.
